Clinical Trial Update: Tocilizumab in Active Moderate-severe Graves' Orbitopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating tocilizumab for active moderate-to-severe Graves' ophthalmopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Conditions: Graves Ophthalmopathy | Phase 2 | Status: UNKNOWN